Cardiac Biomarkers in End-Stage Renal Disease by Leo Jacobs et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Cardiac Biomarkers in End-Stage Renal Disease 
Leo Jacobs, Alma Mingels and Marja van Dieijen-Visser 
Department of Clinical Chemistry, Maastricht University Medical Centre (MUMC) 
The Netherlands 
1. Introduction   
Patients with end-stage renal disease (ESRD) often suffer from cardiovascular complications 
and comorbidities. For example, 55% of ESRD patients suffer from congestive heart failure 
(CHF) and cardiovascular diseases account for the majority of deaths among ESRD patients 
(Herzog, Ma, & Collins, 1998; National Institutes of Health; National Institute of Diabetes 
and Digestive and Kidney Diseases; Bethesda, 2007). It is, therefore, of great importance to 
diagnose the underlying cardiac pathologies and to provide accurate risk stratification in 
ESRD patients.  
Over the years, a number of accurate and sensitive biochemical markers have been 
introduced that have greatly advanced the diagnosis and risk stratification of cardiovascular 
diseases. The most prominent of these biochemical markers are the cardiac troponins (cTn, 
either T or I) and the brain natriuretic peptides (BNPs) and their use has revolutionized the 
diagnosis and risk stratification of acute coronary syndromes (ACS) and CHF respectively 
(A. S. Maisel et al., 2002; Thygesen, Alpert, & White, 2007). However, in the setting of ESRD, 
cardiac troponin concentrations can be elevated in the absence of apparent cardiac damage 
or clinical symptoms (Apple, Murakami, Pearce, & Herzog, 2004; Aviles et al., 2002; C. 
deFilippi et al., 2003; Havekes et al., 2006; Sommerer, Beimler, et al., 2007). Similarly, BNP 
and N-terminal proBNP (NT-proBNP) concentrations are virtually always increased in 
ESRD patients (Apple et al., 2004; Madsen et al., 2007). The presence of such continuously 
elevated cardiac troponin, BNP and NT-proBNP concentrations can interfere with their 
diagnostic and prognostic potential in ESRD patients (David et al., 2008; Pimenta et al., 2009; 
Wu et al., 2007).  
In this chapter, we will elaborate on the frequency of these cardiac biomarker elevations and 
discuss the underlying mechanisms behind them. In addition, we discuss the diagnostic and 
prognostic impact of these elevations and present approaches to improve the usefulness of 
cTn, BNP and NT-proBNP measurements.  
2. The cardiac troponins 
The troponin complex consists of three proteins, troponin C (TnC), troponin I (TnI) and 
troponin T (TnT) that together with tropomyosin regulate the affinity of actin towards 
myosin during muscle contraction  (Kobayashi, Jin, & de Tombe, 2008), as illustrated in 
Figure 1. The troponin complex is present in all striated muscles, but different isoforms of 
troponin I and T exist in skeletal and cardiac tissue. This tissue specific expression of cardiac 
troponin I (cTnI) and cardiac troponin T (cTnT) isoforms within the heart has enabled the 
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development of immunoassays that can specifically detect troponin originating from the 
heart (Cummins, Auckland, & Cummins, 1987; Katus et al., 1989). Nowadays, the cTns have 
become the biomarker of choice for the detection of myocardial injury and play an integral 
part in the diagnosis of ACS. According to current guidelines, (Morrow et al., 2007; 
Thygesen, Alpert, & White, 2007) an AMI is diagnosed when an increase or decrease in 
cardiac biomarker concentrations (preferably cTn), above the 99th percentile of the upper 
reference limit (URL) is detected, in combination with evidence of myocardial ischemia, as 
detected, either by clinical symptoms, electrocardiographic changes or imaging evidence. 
Additionally, the guidelines state that the cTn-assays should be able to measure the 99th 
percentile concentrations with a coefficient of variation (CV) smaller than 10%(Thygesen, 
Alpert, & White, 2007). Ideally, blood samples for the measurements of cTn should be 
drawn on first assessment (after the onset of clinical symptoms) and 6-9 hours later in order 
to detect a rising or falling pattern, as can be interpreted from Figure 2. However, cTn levels 
can remain elevated for some time and the diagnostic window for diagnosing AMI can 
remain open for several days after the onset of symptoms (e.g. when a patients presents > 24 
hours after onset of symptoms).  
 
 
Fig. 1. The release of cTn from damaged cardiomyocytes.  
Most of the studies investigating cTnT and cTnI elevations outside of AMI have been 
performed using immunoassays that lack sufficient analytical performance to accurately 
detect cTn concentrations in healthy subjects. As illustrated in Figure 3, most of the current 
cTn assays have either the limit of detection (LOD) of the assay higher than the reference 
concentrations or the CV exceeds 10% at the 99th URL (Giannitsis & Katus, 2004; Panteghini, 
2006; Panteghini et al., 2004). Highly sensitive assays with the ability to accurately measure 
cTn values even in healthy subjects have been developed recently for cTnT (Giannitsis et al., 
2010) and cTnI (F.S. Apple, 2009; Todd et al., 2007). The increased sensitivity may improve 
the prognostic power of cTn measurements and may enhance identification of subjects at  
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Fig. 2. The release kinetics of cTn after AMI.   
risk. Indeed, two recent studies have shown the prognostic value of cTnT at previously 
undetectable levels in patients with stable coronary disease (Omland et al., 2009) and with 
stable chronic HF (Latini et al., 2007). Moreover, cTnT values measured by a high sensitive 
cTnT assay (hs-cTnT) that were undetectable with the conventional assay were found to be 
associated with the extent of coronary atherosclerosis (Laufer et al., 2010). Figure 1 
visualizes the release of the cTns in response to cellular damage and figure 2 shows the 
typical release kinetics of the cTns seen after an acute myocardial infarction. 
2.1 Cardiac troponin elevations in ESRD 
In patients suffering from ESRD, cTn concentrations can be elevated in the absence of 
apparent cardiac damage or clinical symptoms (Apple et al., 2004; Aviles et al., 2002; C. 
deFilippi et al., 2003; Havekes et al., 2006; Sommerer, Beimler, et al., 2007).  The exact 
frequency of these elevations varies somewhat between studies, depending on the patient 
inclusion criteria, the applied cut-off values and the troponin assay used. In general, cTnT 
has been found elevated more often than cTnI (roughly 53% for cTnT and 17% for cTnI as 
reviewed in (Kanderian & Francis, 2006)) although recent publications, using more sensitive 
assays suggest that the frequency of cTnT and cTnI elevations are similar (Hickman et al., 
2007; Kumar, Michelis, Devita, Panagopoulos, & Rosenstock, 2010). It is important to note 
that the number of detected cTn elevations depends on the cut-offs that are used to define 
elevated values. As mentioned above, many cTn assays lack the sensitivity to accurately 
(<10% CV) measure the 99th percentile and the 10% CV is used as the diagnostic cut-off 
value. As a result the number of elevations will inevitably be lower when higher cut-off 
values are used. For example, in a study that we (Jacobs et al., 2009) performed in 32 ESRD 
patients we found that 38% of patients had cTnT elevations at baseline using the 10% CV 
cut-off, versus 63% using the 99th percentile cut-off with the contemporary 4th generation 
cTnT assay (Roche Diagnostics). Similarly cTnI concentrations where elevated above the 
10% CV in 10% of the cases, compared to 50% elevations above the 99th percentile. Note that, 
the 10% CV is a property solely dependent on the sensitivity of the cTn assay and one 
should not compare cTn elevations above this level between assays. The introduction of 
guideline acceptable cTn assays that can accurate measure the 99th percentile will enable a 
better comparison of the frequencies of cTn elevations in ESRD patients. 
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Fig. 3. (A) Biomarkers within the blood circulation follow a bell-shaped Gaussian 
distribution within a group of subjects. The diagnostic cut-off concentration for cTn is 
defined at the 99th percentile as measured in a healthy reference control group, so 1% of 
these subjects with the highest cTn concentrations are defined unhealthy (Apple et al., 2007; 
Morrow et al., 2007; Thygesen, Alpert, White, et al., 2007). At the time of definition, cTn 
concentrations were undetectable in all healthy individuals, as illustrated by decision limit 
‘b’. Improvements in the lower measuring range have lately resulted in cTn reference 
concentrations and thus also a true 99th percentile concentration. The lower decision limit is 
indicated by ‘a’. However, this improvement in sensitivity = TP/(TP+FN) goes along with a 
worsening of the specificity = TN/(TN+FP). TP, number of subjects that were truly assigned 
positive; FN, number of subjects that were falsely assigned negative; TN, number of subjects 
that were truly assigned negative, FP, number of subjects that were falsely assigned positive; 
(B) A typical precision profile of an immunoassay. The diagnostic cutoff concentration 
should be measured with sufficient precision (coefficient of variation, CV = SD/mean 
<10%)(Panteghini et al., 2004). 
In general, the use of more sensitive cTn assays will likely show that the presence of cTn 
elevations in ESRD patients might be even more frequent than previously thought. We 
found, that by using a more sensitive cTnT assay 94% of our patients had cTnT elevations 
above the 99th percentile with the hs-cTnT assay (Jacobs et al., 2009). Others have similarly 
found a larger amount of cTnI elevations in ESRD patients by using more sensitive cTnI 
assays (Hickman et al., 2007; Kumar et al., 2010). 
With respect to the occurrence of cTn elevations in ESRD patients one should also take into 
account that the cTn concentrations in ESRD patients can vary over time, even in otherwise 
clinically stable patients. For example, by measuring cTn concentrations every two months, 
for a period of 6 months an additional number of patients with elevated cTn concentrations 
(at least once during the follow-up) could be identified (Jacobs et al., 2009). Similarly Roberts 
et al. have also shown longitudinal changes in the presence or absence of cTnT elevations in 
ESRD patients during a 1 year follow-up. In their study, cTnT values were measured 5 times 
A 
cTn (concentration)
C
V
 (
%
)
10
acceptable precision
healthy
population
diseased
patients
decision limit
a b
TN TP
cTn (concentration)
fr
e
q
u
e
n
c
y
tr
u
e
9
9
th
 p
e
rc
e
n
ti
le
FPFN
B
www.intechopen.com
 
Cardiac Biomarkers in End-Stage Renal Disease 
 
151 
and interestingly the patient survival decreased with increasing occurrence of cTnT 
elevations, i.e. the 1.7 year patients survival was 100%, 90% and 78% for patients with zero, 
one to four, or five out of five concentrations (Roberts et al., 2009). These findings are in line 
with above mentioned prognostic value of cTn elevations in ESRD patients. As such, 
assessing cTn concentrations at regular points in time would therefore appear as a 
sensible tool to increase clinical vigilance for the presence of myocardial damage and as a 
means for possible intervention. This is in agreement with previous studies which 
provided evidence for the increased ability of serial versus single cTn measurements to 
identify patients at risk for an event (Han, Lindsell, Ryan, & Gibler, 2005; Miller et al., 
2007; Ooi, Zimmerman, Graham, & Wells, 2001; Roberts et al., 2004; Wayand, Baum, 
Schatzle, Scharf, & Neumeier, 2000). 
2.1.1 Mechanisms underlying the cTn elevations 
The underlying mechanisms behind these elevations have not been fully elucidated. The 
high incidence of coronary artery disease in ESRD patients (National Institutes of Health; 
National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, 2007) and the 
close relationship between cTn levels and the severity of coronary artery disease (C. 
deFilippi et al., 2003; Ooi, Isotalo, & Veinot, 2000) make the presence of subclinical ischemic 
cardiac damage a possible cause of cTn elevations. In this respect, it is also interesting to 
mention a study by DeFillipi et al. (C. R. deFilippi, Thorn, et al., 2007) who compared 
elevated cTnT values in 23 ESRD patients, with evidence of myocardial ischemia gathered 
by means of cardiovascular magnetic resonance (CMR) with late gadolinium enhancement 
(C. R. deFilippi, Thorn, et al., 2007). This study found that only a very small number of 
patients with elevated cTnT had CMR evidence of myocardial damage (0% of patients with 
cTnT <0.03 µg/L and 23% of patients with cTnT > 0.07 µg/L) (C. R. deFilippi, Thorn, et al., 
2007). So, these patients, without known coronary artery disease and virtually no evidence 
of myocardial ischemia still had elevated cTnT values. These findings suggest there may be 
other than ischemia related reasons for the elevated levels of cTn. For example, the dialysis 
process itself can have a direct effect on cTn concentrations. There is some debate as to 
whether the dialysis process causes a decrease in cTn values (Montagnana et al., 2008) or an 
increase (Sommerer, Heckele, et al., 2007). In any case, different dialysis modalities like the 
use of high- or low- flux membranes and the method of vascular access can influence cTn 
concentrations (Lippi et al., 2008; Sommerer, Heckele, et al., 2007). For this reason, blood 
sampling times should be taken into account when measuring cTn concentrations and 
measurements are probably best performed pre-dialysis. 
Another possible reason for the elevated cTn values in ESRD pertains to a decreased renal 
clearance of cTn. For example, the cTn half-life was shown to increase with the degree of 
renal impairment (Wiessner et al., 2007). Diris et al. (Diris et al., 2004) have shown the 
presence of immunoreactive cTnT fragments, which are small enough to be cleared by the 
kidneys and which might accumulate in ESRD patients. Others, however, have found only 
intact cTnT in patients with kidney failure, (Fahie-Wilson et al., 2006) and to date there is 
still a great deal of debate on the mechanisms underlying the cTn elevation in ESRD 
patients. Whatever the exact mechanism, the elevations should not be taken lightly as they 
are highly predictive for adverse cardiovascular events (Apple, Murakami, Pearce, & 
Herzog, 2002; Khan, Hemmelgarn, Tonelli, Thompson, & Levin, 2005; Sommerer, Beimler, et 
al., 2007). 
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2.2 Diagnosing AMI in ESRD 
The presence of continuously elevated cTn concentrations can frustrate the diagnosis of AMI 
(eg. when ESRD patients are presenting with clinical symptoms). The National Academy of 
Clinical Biochemistry (NACB) has recognized this issue and has published guidelines that 
address this issue (Wu et al., 2007). These guidelines suggest that for patients with 
chronically elevated concentrations of cTn, changes in cTn (>20%) 6-9 hours after the onset 
of clinical symptoms are indicative of an AMI. To date, however, little is known about the 
analytical and biological variations of cTn in ESRD patients and >20% changes might also 
occur in the absence of clinical symptoms (Miller et al., 2007; Roberts et al., 2004). The lack of 
detailed knowledge of the biological variation in ESRD patients, in combination with the 
likely increase in the frequency of chronically elevated cTnT as a result of more sensitive 
measurements call for further refinement of the current guidelines. As the highly sensitive 
cTn assays will enable a more accurate assessment of the biological variation, the use of 
serial measurement in order to detect abnormal changes in cTn values will likely be 
incorporated into these refinements. A potential approach to incorporate the biological 
variation into the diagnosis of AMI could come from the use of reference change values 
(RCV) (Aakre & Sandberg, 2010). The RCV describes the change in a concentration between 
two time points, than can be perceived as significant, taking into account both the analytical 
and the individual (biological) variations and is calculated as follows: 
2 22 A IRCV z CV CV= × × +  
wherein z is the z score, which can be set at the desired level of statistical significance. The 
analytical variation is described by the CVA and the individual (biological) variation by the 
CVI (Omar, van der Watt, & Pillay, 2008). To date, there are only a few studies that 
investigated the RCV values for cTnT (Vasile, Saenger, Kroning, & Jaffe, 2010) and cTnI 
(Wu, Lu, Todd, Moecks, & Wians, 2009) in healthy subjects and more studies are needed to 
examine the strengths and weaknesses of using RCV values for the diagnosis of AMI. The 
CVI for cTn can vary from population to population and can depend on the sampling time-
intervals. For example, it has to be investigated if the variations in the cTn measurements 
seen in dialysis patients (i.e. (Hill, Cleve, Carlisle, Young, & McQueen, 2009; Jacobs et al., 
2009)) are comparable to those in “healthy subjects” and if they are diagnostically relevant. 
So, in order to define the biological variations, clear rules need to be established with respect 
to the inclusion of subjects, sampling times, storage etc. Moreover, the variations in 
otherwise healthy subjects may vary from those in diseased populations. 
3. The natriuretic peptides 
The damage to the heart that is sustained during an AMI, but also other disorders that can 
impair left ventricular myocardial function, can lead to heart failure (HF). In HF there is a 
structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or 
eject blood(Hunt, 2005). In effect, the pump-function of the heart is impaired, which may 
lead to symptoms of dyspnea, fatigue and fluid retention. In the population over the age of 
65, the incidence of HF is about 1 per 100 and within this age group it is the leading cause of 
hospitalization (in the United States) (Lloyd-Jones et al., 2002). Considering the wide variety 
of causes underlying HF, the diagnosis and risk stratification in these patients is difficult. 
Over the years several advances have been made and the use of cardiac biomarkers, notably 
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Brain Natriuretic Peptide (BNP) and N-terminal proBNP (NT-proBNP) has greatly 
advanced the physicians ability to identify patients with HF(A. S. Maisel et al., 2002) and to 
provide accurate risk stratification in this population(Christ et al., 2007). 
The natriuretic peptides encompass a number of hormones that are involved in the 
regulation of fluid homeostasis. These hormones include arterial natriuretic peptide (ANP), 
B-type natriuretic peptide (BNP) and C-type natriuretic peptide of which BNP is the most 
important marker for the diagnosis of congestive heart failure. Physiologically, BNP plays 
an important role in the regulation of blood pressure; it induces natriuresis and diuresis, 
acts as a vasodilator and inhibits the renin-angiotensin system (Levin, Gardner, & Samson, 
1998). The synthesis of BNP begins in the ventricular myocytes with the production of a 
precursor protein (Pre-proBNP) that is intracellularly converted to the prohormone proBNP. 
This prohormone is released into the bloodstream in response to increased hemodynamic 
stress (i.e. mechanical stretch seen during volume overload). Upon release into the 
circulation, the proBNP is split into the biologically active BNP and the inactive NT-proBNP 
(figure 4), although recent data suggest that proBNP itself also remains present in the 
bloodstream (Lam, Burnett, Costello-Boerrigter, Rodeheffer, & Redfield, 2007).  
 
 
         
 
 
 
 
 
 
 
 
 
 
Fig. 4. The synthesis and release of BNP. 
BNP and NT-proBNP concentrations correlate with the severity of left ventricular 
dysfunction (Wieczorek et al., 2002) and congestive heart failure (A. S. Maisel et al., 2002; 
Wieczorek et al., 2002) and are highly predictive of adverse events in patients who have 
suffered an AMI (Omland et al., 2002). Overall, BNP and NT-proBNP have equal diagnostic 
and prognostic value in chronic and acute heart failure (Clerico, Fontana, Zyw, Passino, & 
Emdin, 2007; Masson et al., 2006). However, NT-proBNP is more stable than BNP and can 
be collected in serum, heparin  and EDTA plasma (Barnes, Collinson, Galasko, Lahiri, & 
Senior, 2004) , making NT-proBNP slightly more practical in use.   
Clinically, the use of BNP and NT-proBNP has been particularly successful in the diagnosis 
of heart failure in patients with acute dyspnea and in ruling out heart failure (Hobbs et al., 
2002) (Januzzi et al., 2005). There are, however, various factors that can influence the BNP 
and NT-proBNP concentrations which can interfere with their diagnostic and prognostic 
potential. For example, NT-proBNP is influenced by age, gender and obesity (A. Maisel, 
2001; Mehra et al., 2004; Wang et al., 2002) and in particular by renal dysfunction (van 
Kimmenade et al., 2009; Vickery et al., 2005). 
Pre-proBNP 
signal peptide proBNP 
NT-proBNP BNP 
www.intechopen.com
 
Chronic Kidney Disease and Renal Transplantation 
 
154 
3.1 BNP and NT-proBNP elevations in ESRD 
In patients with ESRD, the BNP and NT-proBNP concentrations are virtually always 
elevated above normal cut-off values (Apple et al., 2004; Madsen et al., 2007). There are 
several mechanisms that could explain the elevated BNP and NT-proBNP concentrations. In 
the first place there might be a lack of renal clearance as BNP and NT-proBNP have been 
shown to be inversely correlated to the glomerular filtration rate (reviewed in (C. DeFilippi, 
van Kimmenade, & Pinto, 2008). Interestingly, it is not clear if BNP and NT-proBNP are 
affected similarly by the reduction in renal clearance. Some reports mention that NT-
proBNP is more strongly influenced by a decrease in renal function than BNP, (Vickery et 
al., 2005) whereas others state that they are equally dependent on the renal function for their 
clearance (van Kimmenade et al., 2009). It should be mentioned that the discrepancies 
between NT-proBNP and BNP increase with a decreasing glomerular filtration rate, as 
illustrated by the significantly higher NT-proBNP/BNP ratios in patients with a decreased 
renal function (Kemperman, van den Berg, Kirkels, & de Jonge, 2004; Srisawasdi, 
Vanavanan, Charoenpanichkit, & Kroll, 2010; van Kimmenade et al., 2009; Vickery et al., 
2005). In particular in patients with a severely reduced renal function (eg. eGFR < 20) the 
NT-proBNP/BNP seems to increase exponentially (Srisawasdi et al., 2010; Vickery et al., 
2005). Recent reports in ESRD patients suggest that the NT-proBNP/BNP ratio increases 
even further in patients receiving hemodialysis (Jacobs, Mingels, et al., 2010).  This increase 
in the NT-proBNP ratio might not be the sole result of renal clearance and other mechanism 
such as the extra-renal clearance by circulating type-C natriuretic peptide receptor and by 
neural endopeptidases (Martinez-Rumayor, Richards, Burnett, & Januzzi, 2008) may play a 
role (van Kimmenade et al., 2009). Specifically in ESRD patients, there are several other 
factors that can influence BNP or NT-proBNP concentrations. For example, the dialysis 
process itself may influence BNP and NT-proBNP concentrations, like the type of dialysis 
membrane  Interestingly, some find elevated levels of NT-proBNP after dialysis (Sommerer, 
Heckele, et al., 2007) whereas others find lower values (Madsen et al., 2007), and for BNP 
this might be different than for NT-proBNP (Wahl, Graf, Renz, & Fassbinder, 2004). Other 
parameters, related to the dialysis treatment, such as a patient’s volume status could also 
affect NT-proBNP and BNP concentrations (Booth, Pinney, & Davenport, 2010; Jacobs, van 
de Kerkhof, et al., 2010) whereby, an increase in extracellular volume might induce left 
ventricular dilatation and subsequent increases in (NT-pro)BNP concentrations. More 
research is needed to understand the renal and extra-renal clearance of BNP and NT-
proBNP and to identify ESRD related differences in the clearance or production of these 
peptides. 
3.2 The clinical relevance of (NT-pro)BNP in ESRD 
Regardless of the fact that virtually all ESRD patients have elevated (NT-pro)BNP values 
and that there is much uncertainty about the underlying reasons one should keep in mind 
that the (NT-pro)BNP concentrations still have a strong prognostic value in ESRD patients. 
BNP and NT-proBNP are related to cardiovascular disease and all-cause mortality and thus 
their measurement remains of importance for diagnosis and risk stratification in ESRD 
patients (Apple et al., 2004; Madsen et al., 2007). Importantly the diagnostic and prognostic 
cut-off values for NT-proBNP in ESRD are significantly elevated compared to the cut-off 
values in patient with non or mildly impaired renal function. For example, in hemodialysis 
patients a NT-proBNP cut-off value ≥7200 ng/L could discriminate patients with LVD from 
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those without (David et al., 2008). More in general, DeFilippi et al found an upward shift in 
the optimal cut-off value for patients with a diminished renal function based on the 
estimated glomerular filtration rate (eGFR) (C. R. Defilippi, Seliger, Maynard, & 
Christenson, 2007). The optimal NT-proBNP cut-off for diagnosis of decompensated HF for 
patients (n=831) with eGFR <60 and ≥60 mL/min/1.73 m2 was achieved at concentrations as 
high as 1200 ng/L and 900/450 ng/L (age ≥50/<50 years), respectively. For BNP, optimal 
cut-offs for patients with eGFR <30, 30-59, 60-90, >90 mL/min/1.73 m2 were 225, 201, 104, 
and 71 ng/L, respectively. For optimal diagnostic performance of (NT-pro)BNP in ESRD 
patients, it is thus of great importance that appropriate cut-off concentrations will be 
developed. 
4. Conclusion  
While a reduced renal function and the dialysis treatment itself can have a significant 
influence on cardiac troponin and (NT-pro)BNP values they are strongly associated with 
adverse outcomes. Similarly, the cardiac troponins, which are often elevated above the 
diagnostic cut-off value for AMI provide valuable diagnostic and prognostic information in 
ESRD patients.  
Considering the ESRD related processes that can influence the cardiac troponin and 
natriuretic peptide concentrations, more research is needed to define appropriate cut-off 
values for the diagnosis of AMI and CHF. As both cTn and (NT-pro)BNP concentrations are 
independently associated with cardiovascular mortality, their measurement is important for 
risk stratification and as a tool to increase clinical vigilance.  
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